[1] 支阳,董一诺,茅益民.2024年度药物性肝损伤领域研究进展.中华肝脏病杂志,2025,33(2):125-127. [2] BjÏrnsson HK, BjÏrnsson ES. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med,2022,97:26-31. [3] Rani J, Dhull SB, Rose PK,et al. Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective. Phytomedicine,2024,122:155142. [4] Germani G, Battistella S, Ulinici D, et al. Drug induced liver injury: from pathogenesis to liver transplantation. Minerva Gastroenterol (Torino),2021,67(1):50-64. [5] Ahmad J, Barnhart HX, Bonacini M,et al. Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol,2022,76(5):1070-1078. [6] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 实用肝脏病杂志,2017,20(2):S1-S18. [7] BjÏrnsson ES. Clinical management of patients with drug-induced liver injury (DILI). Uni Eur Gastroenterol J,2021,9(7):781-786. [8] Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int,2022,42(9):1999-2014. [9] Gerussi A, Natalini A, Antonangeli F,et al. Immune-mediated drug-induced liver injury: immunogenetics and experimental models. Int J Mol Sci,2021,22(9):4557. [10] Skat-Rørdam J, Lykkesfeldt J, Gluud LL,et al. Mechanisms of drug induced liver injury. Cell Mol Life Sci,2025,82(1):213. [11] Cunningham M, Gupta R, Butler M. Checkpoint inhibitor hepatotoxicity: pathogenesis and management.Hepatology,2024,79(1):198-212. [12] Liu Q, Huang L, Yan H, et al. Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury. Front Pharmacol,2024,15:1406454. [13] 李勇,张蕾,吴幸福. 老年药物性肝损伤患者临床特征分析. 实用肝脏病杂志,2024,27(4):547-550. [14] 莫伟斌,欧阳婉爱,黄晓涵,等. 80例药物性肝损伤患者临床特征与预后分析. 实用肝脏病杂志,2025,28(1):72-75. [15] Suzuki A, MinjunChen. Epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs. Liver Int,2025,45(4):16146. [16] Abdulkhaleq FM, Alhussainy TM, Badr MM, et al. Antioxidative stress effects of vitamins C, E, and B12, and their combination can protect the liver against acetaminophen-induced hepatotoxicity in rats. Drug Des Devel Ther, 2018,12:3525-3533. [17] LiY, Xu J, Chen W, et al. Hepatocyte CD36 modulates UBQLN1-mediated proteasomal degradation of autophagic SNARE proteins contributing to septic liver injury. Autophagy,2023,19(9):2504-2519. [18] Wang P, Yang Y, Pang G, et al. Hepatocyte-derived MANF is protective for rifampicin-induced cholestatic hepatic injury via inhibiting ATF4-CHOP signal activation. Free Radic Biol Med,2021,162:283-297. [19] Kalas MA, Chavez L, Leon M, et al. Abnormal liver enzymes: a review for clinicians. World J Hepatol,2021,13(11):1688-1698. [20] Ezhilarasan D. Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms. Drug Metab Rev,2023,55(3):239-253. [21] Shah T, Joslyn JA, Lai J. Ceftazidime induced liver injury. BMJ Case Rep,2021,14(12):246571. |